Maze Financial Statements From 2010 to 2025

MAZE Stock   42.10  0.02  0.05%   
Maze Therapeutics,'s financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Maze Therapeutics,'s valuation are provided below:
Market Capitalization
B
Enterprise Value Revenue
369.0066
Earnings Share
(2.56)
Maze Therapeutics, Common does not presently have any fundamental ratios for analysis.
Check Maze Therapeutics, financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Maze Therapeutics,'s main balance sheet or income statement drivers, such as Net Interest Income of 3.2 M, Interest Income of 3.2 M or Depreciation And Amortization of 3 M, as well as many indicators such as Price To Sales Ratio of 3.34, Dividend Yield of 0.0 or PTB Ratio of 3.37. Maze financial statements analysis is a perfect complement when working with Maze Therapeutics, Valuation or Volatility modules.
Check out the analysis of Maze Therapeutics, Correlation against competitors.

Maze Therapeutics, Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets169.4 M240.5 M151.9 M
Pretty Stable
Short and Long Term Debt Total28.9 M26.6 M32.6 M
Pretty Stable
Other Current Liabilities10.3 M14.1 M14.2 M
Slightly volatile
Total Current Liabilities15.4 M20.7 M20.2 M
Slightly volatile
Total Stockholder Equity113.1 M196.9 M102.4 M
Very volatile
Property Plant And Equipment Net28.3 M29.9 M39.3 M
Slightly volatile
Accounts PayableM1.9 M1.7 M
Slightly volatile
Cash119.5 M196.8 M102.8 M
Pretty Stable
Non Current Assets Total32 M38.9 M42.4 M
Slightly volatile
Non Currrent Assets Other8.3 M7.9 M2.2 M
Slightly volatile
Cash And Short Term Investments119.5 M196.8 M102.8 M
Pretty Stable
Common Stock Shares Outstanding48.2 M43.8 M44.1 M
Slightly volatile
Liabilities And Stockholders Equity169.4 M240.5 M151.9 M
Pretty Stable
Non Current Liabilities Total25.6 M23 M28.4 M
Pretty Stable
Capital Lease Obligations23.5 M26.6 M31 M
Slightly volatile
Other Current Assets4.3 M4.9 M5.9 M
Slightly volatile
Other Stockholder Equity30 M47.2 M16.6 M
Slightly volatile
Total Liabilities41 M43.6 M48.5 M
Very volatile
Property Plant And Equipment Gross39.1 M46.8 M49.8 M
Slightly volatile
Total Current Assets125.4 M201.7 M108.8 M
Pretty Stable
Capital Stock1.6 K1.8 KK
Slightly volatile
Net Working Capital104.2 M181 M88.3 M
Pretty Stable
Short Term Debt4.9 M4.6 M4.4 M
Slightly volatile
Common Stock1.9 KK18.7 K
Slightly volatile
Long Term Debt16.1 M18.1 M19.7 M
Slightly volatile
Non Current Liabilities Other775.2 K872.1 K950.8 K
Slightly volatile

Maze Therapeutics, Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Net Interest Income3.2 M4.7 M2.3 M
Slightly volatile
Interest Income3.2 M4.7 M2.3 M
Slightly volatile
Depreciation And AmortizationM3.3 M3.8 M
Slightly volatile
Selling General Administrative27.1 M26.4 M23.4 M
Slightly volatile
Other Operating Expenses85.2 M109.9 M108.6 M
Slightly volatile
Research Development65.5 M83.5 M85.6 M
Slightly volatile
Cost Of RevenueM3.3 M3.8 M
Slightly volatile
Total Operating Expenses85.2 M109.9 M108.6 M
Slightly volatile
Reconciled DepreciationM3.3 M3.8 M
Slightly volatile
Income Tax Expense937.6 K1.1 M1.2 M
Slightly volatile

Maze Therapeutics, Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Stock Based Compensation9.2 M9.6 M7.2 M
Slightly volatile
Begin Period Cash Flow28.7 M30.2 M173.9 M
Slightly volatile
Other Cashflows From Financing Activities71.8 M68.4 M10.2 M
Slightly volatile
DepreciationM3.3 M3.8 M
Slightly volatile
Other Non Cash Items10.2 M12.3 M8.7 M
Slightly volatile
Capital Expenditures947.7 K1.1 M1.8 M
Slightly volatile
Total Cash From Financing Activities97.5 M92.8 M14.3 M
Slightly volatile
End Period Cash Flow120.7 M197.9 M104 M
Pretty Stable

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio3.343.754.0923
Slightly volatile
PTB Ratio3.373.547710.3655
Pretty Stable
Book Value Per Share4.724.49592.4731
Slightly volatile
Stock Based Compensation To Revenue0.04610.05180.0565
Slightly volatile
Capex To Depreciation0.350.34790.4685
Slightly volatile
PB Ratio3.373.547710.3655
Pretty Stable
EV To Sales2.522.843.0951
Slightly volatile
Sales General And Administrative To Revenue0.130.140.1549
Slightly volatile
Research And Ddevelopement To Revenue0.40.450.4893
Slightly volatile
Capex To Revenue0.00550.00620.0067
Slightly volatile
Cash Per Share4.724.49382.472
Slightly volatile
Income Quality0.851.45420.8993
Slightly volatile
Current Ratio10.249.75535.5302
Slightly volatile
Tangible Book Value Per Share4.724.49592.4731
Slightly volatile
Graham Number8.789.8910.7776
Slightly volatile
Shareholders Equity Per Share4.724.49592.4731
Slightly volatile
Debt To Equity0.130.13520.5818
Pretty Stable
Capex Per Share0.02980.02620.0406
Slightly volatile
Revenue Per Share3.063.443.7527
Slightly volatile
Interest Debt Per Share0.90.6080.76
Slightly volatile
Debt To Assets0.110.11070.2308
Pretty Stable
Price Book Value Ratio3.373.547710.3655
Pretty Stable
Pretax Profit Margin0.260.290.3133
Slightly volatile
Ebt Per Ebit1.090.92741.0309
Pretty Stable
Operating Profit Margin0.270.310.3371
Slightly volatile
Effective Tax Rate0.01750.01980.0215
Slightly volatile
Company Equity Multiplier1.161.22161.7944
Pretty Stable
Long Term Debt To Capitalization0.540.60.6543
Slightly volatile
Total Debt To Capitalization0.110.11910.2614
Pretty Stable
Debt Equity Ratio0.130.13520.5818
Pretty Stable
Ebit Per Revenue0.270.310.3371
Slightly volatile
Quick Ratio10.249.75535.5302
Slightly volatile
Net Income Per E B T0.780.880.9595
Slightly volatile
Cash Ratio10.09.52025.238
Slightly volatile
Operating Cash Flow Sales Ratio0.360.410.4449
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.10.98491.0217
Pretty Stable
Price To Book Ratio3.373.547710.3655
Pretty Stable
Fixed Asset Turnover4.485.045.4938
Slightly volatile
Debt Ratio0.110.11070.2308
Pretty Stable
Price Sales Ratio3.343.754.0923
Slightly volatile
Asset Turnover0.560.630.6837
Slightly volatile
Net Profit Margin0.250.280.306
Slightly volatile
Price Fair Value3.373.547710.3655
Pretty Stable

Maze Therapeutics, Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Market Cap558.7 M698.5 M689.5 M
Slightly volatile
Enterprise Value688.4 M528.4 M633.1 M
Very volatile

Maze Fundamental Market Drivers

About Maze Therapeutics, Financial Statements

Maze Therapeutics, stakeholders use historical fundamental indicators, such as Maze Therapeutics,'s revenue or net income, to determine how well the company is positioned to perform in the future. Although Maze Therapeutics, investors may analyze each financial statement separately, they are all interrelated. For example, changes in Maze Therapeutics,'s assets and liabilities are reflected in the revenues and expenses on Maze Therapeutics,'s income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Maze Therapeutics, Common. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Total Revenue167.5 M175.9 M
Cost Of Revenue3.3 MM
Stock Based Compensation To Revenue 0.05  0.05 
Sales General And Administrative To Revenue 0.14  0.13 
Research And Ddevelopement To Revenue 0.45  0.40 
Capex To Revenue 0.01  0.01 
Revenue Per Share 3.44  3.06 
Ebit Per Revenue 0.31  0.27 

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether Maze Therapeutics, Common is a strong investment it is important to analyze Maze Therapeutics,'s competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Maze Therapeutics,'s future performance. For an informed investment choice regarding Maze Stock, refer to the following important reports:
Check out the analysis of Maze Therapeutics, Correlation against competitors.
You can also try the Balance Of Power module to check stock momentum by analyzing Balance Of Power indicator and other technical ratios.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Maze Therapeutics,. If investors know Maze will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Maze Therapeutics, listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(2.56)
Return On Assets
(0.27)
Return On Equity
(0.53)
The market value of Maze Therapeutics, Common is measured differently than its book value, which is the value of Maze that is recorded on the company's balance sheet. Investors also form their own opinion of Maze Therapeutics,'s value that differs from its market value or its book value, called intrinsic value, which is Maze Therapeutics,'s true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Maze Therapeutics,'s market value can be influenced by many factors that don't directly affect Maze Therapeutics,'s underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Maze Therapeutics,'s value and its price as these two are different measures arrived at by different means. Investors typically determine if Maze Therapeutics, is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Maze Therapeutics,'s price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.